PMID

Data

Article Title

Organization

Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.

University Of Strathclyde

Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.

University Of Tennessee Health Science Center

Discovery of potent inhibitors of the lysophospholipase autotaxin.

Babraham Research Campus

Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.

University Of Strathclyde

Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

The University Of Georgia

Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1).

Ku Leuven

Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.

The University Of Memphis

The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxin.

Technical University Of Lodz

Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.

The University Of Memphis

Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin.

The University Of Utah

Structure-based design of novel boronic acid-based inhibitors of autotaxin.

The Netherlands Cancer Institute

Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).

University Of Virginia

Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.

University Of Tennessee Health Science Center

Discovery and optimization of boronic acid based inhibitors of autotaxin.

Institute

Characterization of non-lipid autotaxin inhibitors.

The University Of Memphis

Optimization of a pipemidic acid autotaxin inhibitor.

The University Of Memphis

Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors.

University Of Tennessee Health Science Center

Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.

University Of Tennessee Health Science Center

Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

Lilly Research Laboratories

Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.

University Of Memphis

Identification of Potent

The University Of Tokyo

Synthesis, biological evaluation, and molecular docking study of sulfonate derivatives as nucleotide pyrophosphatase/phosphodiesterase (NPP) inhibitors.

University Of Sharjah

Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators.

The Netherlands Institute

Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.

Chungnam National University

Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo.

Boehringer Ingelheim Pharma

Development of autotaxin inhibitors: A series of zinc binding triazoles.

Novartis Institutes For Biomedical Research

Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.

Chungnam National University

Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes.

Takeda California

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fib

Galapagos

Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.

National And Kapodistrian University Of Athens

Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.

Galapagos

Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P

Bristol-Myers Squibb

Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium.

Creighton University

Pharmacological profiles for rat cortical M1 and M2 muscarinic receptors using selective antagonists: comparison with N1E-115 muscarinic receptors.

Mayo Clinic

Structural determinants of inhibitor selectivity in prokaryotic IMP dehydrogenases.

Brandeis University

Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.

Human Biomolecular Research Institute

Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.

University Of Washington At Seattle

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes.

Bristol-Myers Squibb

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.

Parke-Davis Pharmaceutical Research

Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines.

Sapienza University Of Rome